Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07521046 · ClinicalTrials.gov registry record · Phase 1
Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis (RopeRux in Myelofibrosis)
A Phase 1 study, sponsored by University of Utah.
- Not yet
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT07521046: Clinical Trial Phase 1 study, sponsored by University of Utah.
NCT07521046 is a Phase 1 study that has not yet begun recruiting, run by University of Utah. The registered enrollment target is 15 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (75% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07521046, a Phase 1 study, has not yet begun recruiting, sponsored by University of Utah.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this clinical trial is to learn if the study drug ropeginterferon alfa- 2b added to, standard of care, ruxolitinib is safe and effective in treating patients with Myelofibrosis.
Primary Outcome
To assess the safety and tolerability of ropeginterferon alfa- 2b add-on to ruxolitinib in the study population.
Interventions
- DRUG Ruxolitinib
- DRUG ropeginterferon alfa- 2b
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2026-08 |
| Est. Completion | 2030-08 |
| Phase | Phase 1 |
What is known before NCT07521046 opens enrollment
NCT07521046 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (75% lower).
The record links to 0 conditions, and to 2 interventions - of which Ruxolitinib is the first listed.
NCT07521046 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07521046 about?
NCT07521046 is a clinical study titled "Tolerability of Ropeginterferon Alfa-2b Add-on to Ongoing Ruxolitinib Therapy in Myelofibrosis (RopeRux in Myelofibrosis)". The purpose of this clinical trial is to learn if the study drug ropeginterferon alfa- 2b added to, standard of care, ruxolitinib is safe and effective in treating patients with Myelofibrosis.
What is the current status of trial NCT07521046?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2026-08. Estimated completion is 2030-08.
What interventions are being tested in trial NCT07521046?
The interventions under investigation include: Ruxolitinib (DRUG), ropeginterferon alfa- 2b (DRUG).
Who is sponsoring clinical trial NCT07521046?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07521046's enrollment target sits among peer trials
15 1798th of 2000 higher than 157 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia